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Abstract The usefulness of intrabodies as specific inhibitors of
gene function has been extensively demonstrated in cell culture
assays. However, very few experiments have been conducted with
intrabodies expressed in whole organisms. To evaluate the
intrabody technology in Drosophila, we focused on poxn protein,
since its effects can be easily studied. We purified the
recombinant poxn protein. We next isolated three single-chain
variable fragments (scFv) which specifically recognize poxn
protein. Two scFvs, designated K-Poxn2 and K-Poxn4, react
with both denatured and native Poxn with half maximal
inhibition values of 100 nM and 40 nM, respectively. The K-
Poxn5 scFv also recognizes denatured Poxn but either does not
recognize native Poxn or its half maximal inhibition value for
native Poxn is high.
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1. Introduction
Because of the explosive growth in the cloning and sequenc-
ing of genes, a major task for the coming years will be to
unravel the function of these genes. A key element in the
functional analysis of a gene is the capability to inactivate
this gene. It is therefore of crucial importance to develop
gene inactivation techniques which are broad range and sus-
ceptible to precise experimental control. In addition, develop-
ment of techniques for selective gene inactivation would facil-
itate the development of new anti-gene therapies, as well as
novel strains of plants, animals and other industrially impor-
tant organisms that no longer possess a particular undesired
trait.
Intracellularly expressed antibodies are referred to as intra-
bodies. Numerous studies with cell cultures have demon-
strated the feasibility of intrabody-mediated gene modulation
(reviewed in [1^3]).
The results obtained with cell cultures cannot always be
extrapolated to intact multicellular organisms [4]. For in-
stance, studies on cultured cells do not address the question
of non-speci¢c toxic e¡ects in whole organisms because many
functions are likely to go undetected in culture assays. This
limitation may apply to a large number of genes, since genetic
evidence from Drosophila indicates that most organism-lethal
mutations are not cell-lethal [5]. Thus, it would be desirable to
assess the validity of the intrabody approach in whole organ-
isms.
A few studies have already demonstrated the feasibility of
intrabody-mediated gene modulation in plants (for examples
see [6,7]). Further experiments, using di¡erent targets in di¡er-
ent tissues and organs and eventually in a wide range of di¡er-
ent organisms, should allow to assess the general utility of
intrabodies.
Drosophila’s short reproductive cycle, its large body of ex-
perimental data and mutants, and its well-advanced genetics
and molecular biology [8,9] make it particularly well suited for
the study of intrabodies in di¡erent tissues and organs in the
context of a whole organism. As a ¢rst step towards the eval-
uation of intrabody technology in Drosophila, we have fo-
cused on the isolation of genes encoding antibodies speci¢c
for Poxn.
The poxn protein, encoded by the paired box neuro (poxn)
gene, speci¢es poly-innervated, as opposed to mono-inner-
vated, external sense organs in Drosophila [10,11]. Poxn is
responsible for all the di¡erences between mono- and poly-
innervated external sense organs, including the di¡erences in
their axonal pathways and target recognitions in the central
nervous system [12,13].
In this report we describe the puri¢cation of the poxn pro-
tein, and the isolation and characterization of both monoclo-
nal antibodies and scFvs with speci¢cities for Poxn. To our
knowledge, this is the ¢rst study that reports the cloning and
characterization of genes encoding antibodies speci¢c for a
Drosophila gene product. In the accompanying paper, we eval-
uate the intrabody technology in Drosophila using these scFvs.
2. Materials and methods
2.1. Expression and puri¢cation of poxn protein
Escherichia coli strain BL21(DE3) [14] was transformed with plas-
mid pAR3040 [15] harboring the 1.01 kb BamHI cDNA fragment
spanning most of the poxn coding region fused to the T7 promoter
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[10,11]. Poxn was overexpressed as described [16] except that the cul-
ture was supplied with 150 Wg/ml rifampicin 30 min after induction
with 1 mM IPTG. The resulting inclusion bodies were recovered and
Poxn was refolded in vitro according to the previously described pro-
tocols [17,18]. Alternatively, addition of rifampicin was omitted from
the above-mentioned protocol and cells were harvested by centrifuga-
tion, washed with PBS and resuspended in 1/50 volume of PBS con-
taining 1 Wg/ml pepstatin A, 1 mM EDTA and 1 mM PMSF. Soni-
cation was carried out on ice until the cell suspension became clear.
The lysate was centrifuged at 14 000 rpm for 30 min at 4‡C. The
supernatant containing soluble Poxn was recovered, diluted two times
with bu¡er A (50 mM NaCl, 50 mM sodium phosphate, pH 6.7) and
passed through a 0.2 Wm ¢lter. 24 ml of diluted sample was applied at
a £ow rate of 2 ml/min on a MonoS 10/10 column (Pharmacia Bio-
tech) pre-equilibrated with bu¡er A. The column was then washed
with 50 ml of bu¡er A. Bound proteins were eluted with 80 ml of a
linear gradient of 50 mM to 1 M NaCl in 50 mM sodium phosphate,
pH 6.7 at the same £ow rate as above. Fractions of 8 ml were col-
lected. Poxn was mainly present in fractions 12, 13 and 14 as revealed
by SDS-PAGE. The concentration and purity of Poxn were higher in
fraction 12 than in fractions 13 and 14. Fractions 12 from several
rounds of chromatography were pooled, concentrated 3^4 times by
ultra¢ltration using Amicon (cut-o¡ 10 kDa) and then passed through
a 0.2 Wm ¢lter. 5 ml of this sample was chromatographed over a
Superdex 200 gel ¢ltration column in PBS at a £ow rate of 1 ml/
min. Fractions were collected every 4 min and analyzed by SDS-
PAGE. Fractions 6 and 7 which contained Poxn were pooled and
stored at 370‡C until further use.
2.2. Immunization of mice
Adult NMRI and NZB mice (10 of each strain) were each immu-
nized subcutaneously with 15 Wg of Poxn emulsi¢ed with an equal
volume of Freund’s complete adjuvant. After 3 weeks, primed mice
were again immunized as above but with Freund’s incomplete adju-
vant. Seven days later, the serum antibody titers were analyzed by
ELISA and immunolabelling of Drosophila embryos [19]. Four weeks
after the second immunization, the antigen-responding mice received
an intraperitoneal injection of 10 Wg Poxn in PBS. Five days later, the
spleens of mice which gave high titers of K-Poxn antibodies were used
for the isolation of B-lymphocytes.
2.3. Isolation of mAbs
Spleen cells from immune NZB mice were fused with the mouse
myeloma cell line NSO as described [20]. The hybridoma cells were
screened by ELISA and immunolabelling of Drosophila embryos [19].
The determination of mAbs isotypes was carried out using the Inno-
Lia mouse mAb isotyping kit (Innogenetics).
2.4. DNA manipulations
DNA manipulations were carried out following standard proce-
dures [21]. PCR screening of the recombinant clones and PCR-MvaI
and -Sau3AI ¢ngerprinting were as described [22]. Nucleotide sequen-
ces were determined by the dideoxynucleotide chain termination
method [23].
2.5. Library construction
mRNA was prepared from the pooled splenocytes of positive mice
using the QuickPrep Micro mRNA puri¢cation kit (Pharmacia Bio-
tech). The resulting mRNA was then used for ¢rst-strand cDNA syn-
thesis using the Ready-To-Go-T-Primed ¢rst-strand kit (Pharmacia
Biotech). VH and VL genes were ampli¢ed separately from the





TCTCCA-3P) and VLFOR (5P-GCAGCATTCTAGAGTTTGATTT-
CCAGCTTGGTCCC-3P). Each PCR reaction was performed in a 100
Wl volume containing 1^2 Wl of the ¢rst-strand cDNA synthesis mix-
ture, 20 nmol of each dNTP, 20 pmol of each primer, 2.5 units of Taq
polymerase and PCR bu¡er (Boehringer Mannheim). Each PCR cycle
consisted of 1 min denaturation at 94‡C, 2 min annealing at either
51‡C with primer VHBACK-2 or 58‡C with the other primers, and
2 min extension at 72‡C. The VH and VL repertoires were separately
digested with restriction enzymes SpeI and SacI, respectively, to pro-
duce DNA ends free from tailing nucleotides. The digested VH and VL
repertoires were puri¢ed from 1% agarose gel using GeneClean II kit (Bio
101). The linker DNA [24] was ampli¢ed from a recombinant pHEN1
containing a scFv gene with 35 cycles of PCR (94‡C for 1 min, 65‡C for 1.5
min and 72‡C for 1 min) using primers LINKFOR (5P-TGGAGACT-
GGGTCATCACGAGCTCCGATCCGCC-3P) and LINKBACK (5P-
GGGACTCTGGTCACTGTCACTAGTGG-3P). The ampli¢ed linker
was puri¢ed from the gel using MERMAID kit (Bio 101). The gel-
puri¢ed VH and VL repertoires in combination with linker were then
assembled to generate the scFv repertoire as described [25] except that
the ¢rst seven cycles were each carried out at 94‡C for 1.5 min, 51‡C




3P) and VLFOR-NotI (5P-AACAGTTTCTGCGGCCGCAGCATTC-
TAGAGTTT-3P) were then added and the reaction mixture was am-
pli¢ed for 25 cycles (94‡C for 1.5 min, 68‡C for 1.5 min and 72‡C for
2 min). The assembled products were digested with S¢I and NotI, gel-
puri¢ed using GeneClean II kit (Bio 101) and ligated into pHEN1
vector [26]. The ligated DNA was then electroporated into E. coli
XL2Blue-MRFP (Stratagene). After electroporation, cells were grown,
plated and stored as a library stock [22].
2.6. Rescue of phagemid library and panning
Rescue of phagemid particles was as described [22] except that
M13K07 helper phage was used and 45 min after addition of helper
phage, IPTG was added to ¢nal concentration of 1 mM. Rescued
phages were blocked with 1% BSA (w/v) containing the MonoS 10/
10 fractions of an induced culture of E. coli BL21(DE3) harboring
non-recombinant pAR3040 vector. The fractions used correspond to
the ones where Poxn, in lysate from bacteria containing the recombi-
nant vector, elutes. Blocked phages were panned against Poxn as
follows. Wells of 96-well ELISA plates (Nunc-Immuno plate, Maxi-
Sorp) were coated with 60 Wl of 50 Wg/ml Poxn in PBS per well at
room temperature for 4^6 h and blocked with PBS-1% BSA (w/v). In
addition, uncoated wells were blocked as above to serve as negative
control. Phages were incubated in Poxn-coated and negative wells,
unbound phages removed and the bound phagemid particles eluted
and propagated as in [22] except that PBS, 0.02% Tween 20 was
replaced by PBS, 0.05% Tween 20.
2.7. Phage ELISA assays
Rescue of phagemid from individual clones for monoclonal phage
ELISA was carried out as in Section 2.6. Wells of 96-well microtiter
plates were coated with 60 Wl of either 5 Wg/ml Poxn, 500 Wg/ml
lysozyme or 1 mg/ml globH5 [27] in PBS. The remaining protein
binding sites were blocked as for panning. The monoclonal phage
ELISA was performed using 50 Wl of culture supernatant per well
and the detection module of recombinant phage antibody system
(Pharmacia Biotech) according to the manufacturer’s recommenda-
tions. Polyclonal phage ELISA (5U109 phage particles per well)
was as outlined for monoclonal phage ELISA.
2.8. Expression of scFv proteins
ScFv proteins were expressed in E. coli strain TG1. Induction of
protein synthesis and isolation of scFv fragments from the periplasmic
space have been described [28].
2.9. Indirect ELISA using soluble scFv fragments
The coating and blocking of the wells were as described in Section
2.7. 50 Wl of periplasmic extracts was added to each well and incu-
bated for 2 h. The wells were washed ¢ve times with PBS, 0.05%
Tween 20. Anti-c-myc-tag antibody 9E10 was added to each well
and allowed to react for 2 h. The wells were washed as above and
then incubated with anti-mouse IgG-HRP conjugate (Sigma) for 1 h.
After ¢ve washes, binding was detected using ABTS/H2O2 as sub-
strate. All steps were carried out at room temperature.
2.10. ELISA competition test for speci¢city and half maximal
inhibition measurements
The ELISA competition test and half maximal inhibition measure-
ments were performed as in [29,30].
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2.11. SDS-PAGE and Western blotting
SDS-PAGE and Western blot analysis of the proteins separated by
SDS-PAGE were essentially as in [31,32], respectively.
3. Results
3.1. Expression and puri¢cation of the poxn protein
To ensure high levels of expression, Poxn was initially ex-
pressed in the presence of rifampicin. Rifampicin has no e¡ect
on T7 polymerase but inhibits the transcription by E. coli
RNA polymerase, thus increasing the expression of genes
driven by the T7 promoter [16]. Expression of Poxn in the
presence of rifampicin yielded high levels of Poxn which ac-
cumulated as inclusion bodies. The fusion protein appeared in
SDS-polyacrylamide gel with a molecular mass of 47 000 Da
(Fig. 1, lane 2). The inclusion bodies were recovered and used
for puri¢cation and refolding of Poxn (Fig. 1, lane 3). How-
ever, the use of this procedure was hampered by the low
recovery of Poxn as a soluble fraction after refolding, and
by a poor reproducibility. Since the aggregation problem
may be circumvented by lowering the expression levels [33],
the rifampicin was omitted from the expression protocol. This
resulted in lower levels of Poxn but, interestingly, the ex-
pressed protein was found almost exclusively in the soluble
fraction. The soluble Poxn was ¢rst partially puri¢ed from the
E. coli cell lysate supernatant by cation-exchange chromatog-
raphy through a MonoS 10/10 column. The Poxn in fraction
12 was about 60^70% pure as estimated by Coomassie bril-
liant blue staining of proteins resolved by SDS-PAGE (Fig. 1,
lane 4). Fractions 12 from several rounds of chromatography
were used for further puri¢cation of Poxn by gel ¢ltration on
Superdex 200. Poxn was more than 90% pure after gel ¢ltra-
tion (Fig. 1, lane 5). The protein bands with lower electro-
phoretic mobilities than Poxn, present in the sample recovered
after gel ¢ltration, are likely aggregates of Poxn (Fig. 1, lane
5). This conclusion is based on the fact that these bands are
also present in the in vitro refolded sample (Fig. 1, lane 3);
and since Poxn was excised from the gel prior to refolding, it
cannot be contaminated with proteins with migration patterns
so di¡erent from that of Poxn. However, these proteins did
not react with mAbs speci¢c for Poxn (Fig. 2A). This might
be due to the inaccessibility of these antibodies to their cor-
responding epitopes in aggregates because of the possible in-
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Fig. 3. Monoclonal phage ELISA to assay the speci¢city of the
binding of ¢ve clones isolated by panning against Poxn. Clones 2, 4
and 5 represent K-Poxn2, K-Poxn4 and K-Poxn5 scFvs, respectively.
Clones 28 and 50 each contain a truncated VH.
Fig. 2. Analysis of the puri¢ed Poxn and anti-Poxn mAbs. A: West-
ern blot. Protein samples were transferred to nitrocellulose mem-
brane, reacted ¢rst with mAb17B7B10 and then with anti-mouse
IgG-alkaline phosphatase conjugate. Bound antibodies were detected
using NBT/BCIP as substrate. The protein samples are as follows:
lanes 1, 2, 3 and 4, respectively, the same as lanes 1, 2, 4 and 5 in
Fig. 1. B: Immunolabelling of Drosophila embryos [19] with mAb
17B7B10. The immunolabelling pattern precisely parallels the spatial
and temporal patterns of expression of poxn described in [10,11].
Similar results were obtained with mAb 17B7A12.
Fig. 1. SDS-PAGE analysis of protein samples at di¡erent stages of
puri¢cation of Poxn. Various preparations were electrophoresed in
12.5% SDS-polyacrylamide gel and stained with Coomassie brilliant
R-250. Lane MW, molecular weight protein markers, sizes in kDa
are indicated on the left of the ¢gure; lane 1, total lysate of IPTG
induced E. coli BL21 (DE3) cells containing non-recombinant
pAR3040 vector; lane 2, total lysate of IPTG induced E. coli BL21
(DE3) cells harboring recombinant pAR3040 vector containing the
1.01 kb BamHI cDNA fragment of poxn, the arrow indicates the
position of the overexpressed Poxn; lane 3, Poxn excised from SDS-
polyacrylamide gel, electroeluted and refolded in vitro; lane 4, frac-
tion 12 from MonoS 10/10 column (concentrated 4 times); lane 5,
pool of fractions 6 and 7 from Superdex 200 gel ¢ltration column
(concentrated 3 times).
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volvement of these epitopes in aggregation. Although less
likely, we cannot formally exclude the possibility that these
aggregates are composed of proteins other than Poxn.
3.2. Generation of monoclonal antibodies speci¢c
for the poxn protein
To con¢rm that the puri¢ed protein is Poxn, the puri¢ed
protein was used as immunogen for the production of mAbs,
and the mAbs generated against the puri¢ed protein were
tested by immunolabelling of Drosophila embryos for their
speci¢cities for Poxn. The puri¢ed protein did not elicit anti-
bodies in NMRI mice. In contrast, 8 out of 10 NZB mice,
immunized with puri¢ed protein, produced K-Poxn antibod-
ies. However, the mice with the highest titers of K-Poxn anti-
bodies died soon after the second immunization. Hybridomas
were produced using the immune NZB mice. Two mAbs,
17B7A12 and 17B7B10 (IgG1 class), were isolated. Western
blots with either mAb reveals a single reactive band corre-
sponding to the bulk of protein obtained by cation-exchange
chromatography and gel ¢ltration (Fig. 2A). Immunolabelling
of Drosophila embryos shows that these mAbs label speci¢-
cally those Drosophila cells that express Poxn (Fig. 2B). These
experiments con¢rm that the overexpressed and puri¢ed pro-
tein with apparent molecular mass of 47 000 Da is indeed
Poxn.
3.3. Isolation of K-Poxn scFv antibodies
A scFv library was constructed from the VH and VL reper-
toires of NZB mice immunized with Poxn. The library con-
tained 2U107 individual colonies. PCR screening of 100 ran-
domly chosen colonies demonstrated that a full-length scFv
insert was present in 85% of the colonies, whereas about 10%
of the colonies contained a short (probably rearranged) insert.
The insert diversity of recombinant colonies containing a full-
length scFv insert was assessed by PCR-MvaI ¢ngerprinting
and shown to be about 85% (data not shown).The library was
subjected to four rounds of panning against Poxn, and the
speci¢c enrichment values (calculated as the number of phages
eluted from Poxn-coated wells divided by the number of
phages eluted from BSA-coated wells) for scFv phages recog-
nizing Poxn were 14, 14, 21 and 115, respectively, after the
¢rst, second, third and fourth rounds of panning. Polyclonal
mixtures of phagemid particles, produced by repropagation of
the phages eluted after each round of phage selection, were
also tested by ELISA for enrichment of scFv phages speci¢c
for Poxn. A sharp increase of signal was noticed after the
fourth round of panning. The results of polyclonal phage
ELISA were consistent with enrichment values outlined
above.
Following the fourth round of panning, 120 clones obtained
by infection with the eluted phages were individually tested by
ELISA. Out of 120 clones, 68 produced phages that bound to
Poxn. PCR and restriction analyses of these 68 clones dem-
onstrated that two clones, designated clone 28 and clone 50,
have an insert of about 300 bp while other clones have an
insert with the size expected for the scFv fragment. The insert
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Fig. 5. Speci¢city of soluble scFvs. A: Western blot analysis of K-
Poxn scFvs. Proteins were electrophoresed in 12.5% SDS-polyacryl-
amide gel, transferred to nitrocellulose membrane and reacted ¢rst
with scFvs, then with anti-c-myc tag 9E10 antibody and ¢nally with
anti-mouse IgG-alkaline phosphatase conjugate. The bound antibod-
ies were detected by NBT/BCIP as substrate. The protein samples
transferred to membrane are as follows: lanes 1, 3 and 5, total ly-
sate of induced E. coli BL21(DE3) cells containing non-recombinant
pAR3040 vector; lanes 2, 4 and 6, total lysate of induced E. coli
BL21(DE3) cells harboring recombinant pAR3040 vector containing
the 1.01 kb BamHI cDNA fragment of poxn. The scFvs used are as
follows: lanes 1 and 2, K-Poxn2 scFv; lanes 3 and 4, K-Poxn4
scFv; lanes 5 and 6, K-Poxn5 scFv. B: Indirect ELISA assay. Bind-
ing was determined by ELISA to a variety of immobilized proteins:
Poxn (5 Wg/ml), lysozyme (500 Wg/ml), GlobH5 (1 mg/ml) and BSA
(10 mg/ml). Experiments were carried out with periplasmic extracts
of transformed E. coli TG1.
Fig. 4. Amino acid sequence of the anti-Poxn scFvs. The linker sequence is shown in bold and between slashes. The polarity of scFvs is as fol-
lows: VH-linker-VL. CDRs are underlined. Dashes have been introduced to align the CDRs.
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diversity of the 66 putative positive clones with expected insert
size was assessed by PCR-MvaI and -Sau3AI ¢ngerprinting.
Based on MvaI restriction enzyme digestion patterns, three
di¡erent groups were identi¢ed and all clones belonging to
one group had the same Sau3AI restriction enzyme digestion
pattern (data not shown). Therefore, one clone from each
group was chosen for further analysis. These clones were des-
ignated K-Poxn2, K-Poxn4 and K-Poxn5.
3.4. Speci¢city of the reactive phages
To determine the speci¢city of the selected clones, mono-
clonal phage ELISA was carried out using Poxn and two
irrelevant antigens as controls, lysozyme and globH5. Clones
28 and 50 gave similar absorbance values for di¡erent pro-
teins indicative of the polyspeci¢city or sticky behavior of
these clones. Except for clones 28 and 50, absorbance values
obtained with Poxn-coated wells were much higher than those
obtained with wells coated with lysozyme or globH5 (Fig. 3).
Taking into account that in this assay, concentrations of ly-
sozyme and globH5 are, respectively, 100 and 200 times high-
er than that of Poxn, these results con¢rm that K-Poxn2, K-
Poxn4 and K-Poxn5 scFvs are highly speci¢c.
3.5. Sequence analysis of the reactive clones
Fig. 4 shows the amino acid sequence of K-Poxn2, K-Poxn4
and K-Poxn5 scFvs as deduced from the nucleotide sequence.
Each scFv consists of unique VH and VL domains. Clones 28
and 50 carry only a part of a VH sequence but VL is missing
(data not shown), consistent with our previous observation
that only an insert of 300 bp was identi¢ed by restriction
analysis of these two clones.
3.6. Speci¢city of the soluble K-Poxn scFv antibodies
K-Poxn2, K-Poxn4 and K-Poxn5 scFvs were expressed as
soluble antibody fragments. After IPTG induction, a protein
band with an apparent molecular mass of about 29 000 Da
was detected in Western blot with the anti-c-myc 9E10 anti-
body (data not shown). Western blotting experiments with
periplasmic extracts demonstrated that these scFvs speci¢cally
recognize Poxn (Fig. 5A). The same extracts were also
screened by ELISA for binding to a panel of di¡erent proteins
and the scFv fragments were found to be highly speci¢c (Fig.
5B).
3.7. ELISA competition test and half maximal inhibition
measurements
As illustrated in Fig. 6, the binding of K-Poxn2 and K-
Poxn4 scFvs to Poxn coated on solid phase was e⁄ciently
inhibited by preincubating the antibody with 1 WM solution
of native Poxn. This concentration of Poxn did not inhibit the
binding of K-Poxn5 scFv. Therefore, at least, K-Poxn2 and K-
Poxn4 scFvs recognize native Poxn. Irrelevant antigens such
as lysozyme, globH5 and BSA, even if used at much higher
concentrations than Poxn, failed to compete with Poxn for
binding to these scFvs con¢rming that these antibody frag-
ments are indeed speci¢c for Poxn (Fig. 6). To determine the
half maximal inhibition values of the scFvs for Poxn, experi-
ments were performed at constant but non-saturating concen-
trations of the scFvs as determined in the titration ELISA
test. These experiments showed that K-Poxn2 and K-Poxn4
scFvs react with native Poxn with half maximal inhibition
values of 100 nM and 40 nM, respectively (Fig. 7). The anal-
ysis of the binding curves suggests that half maximal inhib-
ition value for K-Poxn5 scFv, if any, is higher than 1 WM (Fig.
7). Alternatively, K-Poxn5 scFv may react only with dena-
tured Poxn.
4. Discussion
Intrabody technology is one of the most novel and promis-
ing developments in the rapidly evolving area of gene modu-
lation technology. Numerous studies on cultured cells have
provided secure foundation for the use of intrabodies as re-
producible, simple, broad-based and speci¢c reagents for the
modulation of gene function (reviewed in [1^3]). To provide a
basis for the evaluation of intrabody technology in Drosophi-
la, we have puri¢ed the Drosophila poxn protein, and isolated
scFv genes that encode antibodies speci¢c for Poxn.
The apparent molecular mass of the Poxn (47 000 Da) ex-
pressed in E. coli is higher than the expected molecular mass
of 38 144 Da calculated from the amino acid composition of
Poxn. The fact that staining pattern of Drosophila embryos
with mAbs that speci¢cally recognize the 47 000 Da protein
precisely parallels the spatial and temporal patterns of the
expression of poxn during embryonic development proves
that the puri¢ed protein is Poxn. As described for Drosophila
fushi tarazu and kruºppel proteins [34,35], the high proline con-
tent (9.2%) of recombinant Poxn may be responsible for its
anomalous migration.
The fact that Poxn did not elicit any detectable antibodies
in NMRI mice suggests that the self-tolerance pro¢le of
mouse may include Poxn. We thus switched to NZB mice
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Fig. 6. ELISA competition test. Wells were coated with 1 WM Poxn
and the binding of soluble scFvs to immobilized Poxn was com-
peted with 1 WM Poxn, 1 WM lysozyme, 4 WM GlobH5 or 150 WM
BSA. The percentage of binding is expressed as follows: [absorbance
(A405) in the presence of competitor divided by absorbance (A405) in
the absence of competitor]U100. The scFv samples used were peri-
plasmic extracts of transformed E. coli TG1.
Fig. 7. Inhibition ELISA to determine half maximal inhibition val-
ues of anti-Poxn scFv fragments. Wells were coated with 1 WM
Poxn and the binding of soluble scFvs to immobilized Poxn was
competed with di¡erent amounts of Poxn. The percentage of bind-
ing is expressed as in legend for Fig. 6.
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which make autoantibodies more easily than other strains and
are therefore recommended for immunization with well-con-
served antigens [31]. Apparently, high titers of K-Poxn anti-
bodies were lethal for these mice, in line with the idea that
these antibodies may indeed cross-react with mouse anti-
gen(s).
Since scFvs with good expression levels and high speci¢c-
ities are readily selected from very large and diverse antibody
libraries, a scFv library was constructed using spleen cells of
the immunized NZB mice. From this library, we ¢rst isolated
¢ve clones giving strong ELISA signals on Poxn. However,
two of these clones, clones 28 and 50, showed strong signals
with irrelevant antigens as well. Since these two clones contain
only a part of a VH, their reactivity with di¡erent antigens
might result from the stickiness of the truncated mouse VH.
Three scFvs show a high speci¢city of binding to Poxn. The
speci¢c recognition of Poxn by these scFvs in Western blot
suggests that these scFvs recognize denatured Poxn. Likewise,
ELISA competition test reveals that at least two of these
scFvs, K-Poxn2 and K-Poxn4, recognize native Poxn as well.
Thus, the epitopes recognized by K-Poxn2 and K-Poxn4 scFvs
are probably linear epitopes that are also exposed in native
Poxn. Binding of K-Poxn5 scFv to Poxn coated on solid phase
was not inhibited by incubation of antibody with 1 WM Poxn,
suggesting that this antibody reacts with an antigenic deter-
minant which is hidden in native Poxn and becomes exposed
upon coating the protein on a solid phase. Alternatively, in
addition to the recognition of denatured Poxn, K-Poxn5 scFv
may react with native Poxn but with high half maximal in-
hibition value. We could not test the latter possibility, because
Poxn aggregates at concentrations above 1 WM.
The monoclonal antibodies isolated in this study can be
used for further analysis of the role of poxn in the develop-
ment of the £y nervous system, as has also been documented
by using these mAbs to isolate and characterize poxn muta-
tions that a¡ect the adult chemosensory organs [36].
In addition, using the K-Poxn scFvs, we demonstrate the
feasibility of intrabody-mediated gene modulation in Droso-
phila (see accompanying paper [37]).
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